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Abstract
Rationale—The widely available hallucinogen salvinorin A is a unique example of a plant-derived
compound selective for κ-opioid receptors and may produce effects distinct from those of other
compounds with classic hallucinogenic or dissociative properties which are also abused in humans.
Objectives—The objective of this study is to characterize the salvinorin A discriminative cue in
nonhuman primates with high κ-receptor genetic homology to humans.
Methods—Adult rhesus monkeys (n=3) were trained to discriminate salvinorin A (0.015 mg/kg,
s.c.) from vehicle, in a food-reinforced operant discrimination assay. Parallel studies, using
unconditioned behavioral endpoints (facial relaxation and ptosis) also evaluated the κ-opioid receptor
mediation of salvinorin A in vivo function.
Results—Monkeys trained to discriminate salvinorin A generalized structurally diverse, centrally
penetrating κ-agonists (bremazocine, U69,593, and U50,488). By contrast, μ- and δ-opioid agonists
(fentanyl and SNC80, respectively) were not generalized, nor were the serotonergic 5HT2
hallucinogen psilocybin or the dissociative N-methyl-D-aspartic acid antagonist, ketamine. The
discriminative effects of salvinorin A were blocked by the opioid antagonist quadazocine (0.32 mg/
kg), but not by the 5HT2 antagonist ketanserin (0.1 mg/kg). Consistent with these findings, salvinorin
and κ-agonists (e.g., U69,593) produce effects in the unconditioned endpoints (e.g., ptosis), whereas
psilocybin was inactive.
Conclusions—These findings support the conclusion that the interoceptive/discriminative cue
produced by salvinorin A is mediated by agonism at κ-receptors and is mechanistically distinct from
that produced by a classic serotonergic hallucinogen.
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Salvinorin A, a diterpenoid, is the main active product from the widely available psychoactive
plant, Salvia divinorum. Salvinorin A is a structurally unique selective agonist at κ-opioid
receptors and also displays particular pharmacodynamic effects at this receptor, including high
efficacy, and low propensity to cause receptor desensitization (Chavkin et al. 2004; Wang et
al. 2004). Salvinorin A-containing products (including concentrated extracts) are widely
available, and their usage for nonmedical purposes in adolescents and young adults has been
described in recent surveys (Khey et al. 2008; Lange et al. 2008; Paglia-Boak et al. 2009;
Substance Abuse and Mental Health Services Administration 2008). A recent large survey
detected prior-year exposure to salvinorin A-containing products in the same order as the
“club” drug N-methyl-D-aspartic acid (NMDA) antagonist, ketamine (Paglia-Boak et al.
2009). Also, the most recent “Monitoring the future” survey reported that approximately 6%
of 12th graders in a large US sample (n=14,268) reported use of S. divinorum products in the
preceding 12 months (Johnston et al. 2009). Salvinorin A is therefore the only high efficacy,
selective κ-agonist to have broad diffusion in the population.
Salvinorin A is a highly potent hallucinogen in humans, as determined from descriptive studies
and self-reports (Gonzales et al. 2006; Siebert 1994). However, there are no quantitative,
laboratory-based reports on its behavioral effects in humans to date. Salvinorin A-containing
preparations are in a legislative flux in the USA, with several states moving to regulate these
products, widely available on the internet (Griffin et al. 2008; Hoover et al. 2007).
Nonhuman primates are particularly valuable subjects to study the effects of κ-opioids, from
a translational perspective. This is due to the relative homology between nonhuman primates
and humans, in terms of κ-receptor neuroanatomical populations, OPRK1 (κ-receptor) genetic
homology, and ability to study neuroendocrine and behavioral endpoints with translational
value (i.e., endpoints that can be easily adapted to human studies; Butelman et al. 2007).
It was originally reported that nonhuman primates trained to discriminate the synthetic κ-
agonist U69,593 generalized salvinorin A (Butelman et al. 2004); similar findings were also
made in rats (Baker et al. 2009; Willmore-Fordham et al. 2007). Given the uniqueness of
salvinorin A as an opioid ligand, and its status as a broadly available psychoactive agent in
legislative flux, it is of interest to determine directly whether the discriminative effects of
salvinorin A itself are shared by structurally diverse synthetic κ-agonists, other opioids, and
by other hallucinogenic/psychotomimetic compounds abused by humans. A recent study
reported that rats trained to discriminate salvinorin A do generalize arylacetamide κ-agonists
(U69,593 and U50,488; Baker et al. 2009). This study will therefore present a salvinorin A
drug discrimination in nonhuman primates, its generalization by structurally diverse κ-agonists
(arylacetamide and benzomorphan), as well as the lack of generalization to a classic
serotonergic hallucinogen, and to the NMDA antagonist, ketamine, also an abused
psychotomimetic agent. We further compared unconditioned behavioral effects of salvinorin
A (facial relaxation and ptosis) with those of a classic serotonergic hallucinogen. Facial
relaxation and ptosis can be studied in humans (Chernik et al. 1990; Miner et al. 2002) without
subject training required for operant variables such as drug discrimination, and therefore, have




Three male, adult, captive-bred, gonadally intact rhesus monkeys (Macaca mulatta; age range,
8–14 years old approximately; weights, 7.8, 8.1, and 9.7 kg) were used in the drug
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discrimination studies. Two other adult males (weights, 10.4 and 12.5 kg) and two adult females
(weights, 6.6 and 8.6 kg) were used in the facial relaxation/ptosis studies (n=4). The subjects
were housed singly in stable colony rooms maintained at 20–22°C with controlled humidity
and a 12:12-h light:dark cycle (lights on at 0700 hours). Subjects in drug discrimination studies
were food restricted to approximately 95% of free-feeding weights; they were fed appropriate
amounts of primate chow biscuits (PMI Feeds, Richmond, VA, USA) daily, supplemented by
appetitive treats. An environmental enrichment plan was in place (with visual and auditory
stimuli) in the colony rooms. Water was available ad lib in home cage, via an automatic
waterspout. All subjects had limited histories of prior exposure to opioid pharmacological
probes, and no history of chronic exposure to any agent or exposure to any psychostimulant.
All sessions were carried out (typically 5 days per week), at least 2 h after lights on and 2 h
before lights out.
Studies were reviewed by the Rockefeller University Animal Care and Use Committee, in
accordance with the Guide for the Care and Use of Animals (National Academy Press;
Washington, DC, USA, 1996).
Drug discrimination
Procedure
Three male subjects were trained to discriminate salvinorin A (0.015 mg/kg, s.c.) from vehicle
in a two-key (fixed ratio) FR task, in operant conditioning chambers (Med Associates, St.
Albans, VT, USA), connected to a computer, via a Med Associates interface.
Training
Subjects were trained in multiple-cycle sessions; each cycle consisted of an initial s.c. injection
followed by a 15-min time-out period (time-out responses had no consequence). At the end of
the time-out period, a 5-min response period started (signaled by stimulus lights above each
lever), during which, monkeys received up to ten sucrose pellets (300 mg; PJ Noyes/Research
Diets; New Brunswick, NJ, USA), by responding on the injection-appropriate (“correct”) lever.
A “reset” contingency was in place, in that an incorrect response reset the FR requirement to
FR8 (one subject) FR12 (two subjects) on the correct lever. A maximum of four cycles occurred
within each training session. In multiple-cycle training sessions, the first cycle was always a
vehicle cycle. If the training drug (salvinorin A, 0.015 mg/kg, s.c.) was administered, it would
always be on the last cycle of the session. Monkeys were typically trained 5 days per week.
Criterion responding was defined as at least 90% injection-appropriate responses, and no more
than 1× FR responses on the incorrect lever before the first food presentation in any cycle, with
response rates of at least 1 response/s. Prior to commencement of testing, each subject reached
criterion responding for five consecutive training days. This occurred for the different subjects
at 68, 116, and 197 training days, respectively.
Testing
Test sessions were identical to those described above, except that 1× FR consecutive responses
on either lever resulted in pellet delivery. Tests followed a cumulative dosing procedure. In
these cumulative dosing tests, doses of the compounds were increased in 0.5 log unit steps
(each cycle commenced with a 15-min time-out period, followed by a 5-min response period,
as mentioned above). Test doses were increased in each subject until either (a) generalization
(i.e., at least 90% salvinorin A-appropriate responding), (b) rates of responding were decreased
by ≥70% vs. control (the mean of the three most recent consecutive vehicle-training cycles
prior to the test session), or (c) the appearance of untoward effects. Tests in the same subject
were separated by at least two consecutive training days at criterion performance (i.e., at least
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90% injection-appropriate responding and no more than 1× FR responses on the incorrect lever
before the first food presentation in any cycle, with responses rates of at least 1 response/s).
Design
Cumulative salvinorin A (0.001–0.01 mg/kg [two subjects], 0.0032–0.01 mg/kg [one subject])
and its vehicle (0.16 ml/kg, in consecutive cycles) were compared to κ-agonists: bremazocine
(0.0001–0.001 mg/kg), U50,488 (0.01–0.032), U69,593 (0.001–0.01 mg/kg), and ICI204,448
(0.01–0.1 mg/kg). Other compounds were also compared under identical cumulative dosing
conditions: fentanyl (0.001–0.032 mg/kg), SNC80 (0.032–0.32 mg/kg), ketamine (0.1–3.2 mg/
kg), and psilocybin (0.032–0.32 mg/kg). In antagonism studies, the cumulative salvinorin A
dose-effect curve was re-determined 60 min after pretreatment with quadazocine (0.32 mg/kg)
or 30 min after pretreatment with ketanserin (0.1 mg/kg; Butelman et al. 2004; Li et al.
2009). Quadazocine and ketanserin control studies were also completed, (i.e., with the
administration of three vehicle test cycles after the appropriate antagonist pretreatment). Each
of the above experiments was carried out as one or two determinations per subject.
Data analysis
The main dependent variable was percent drug (salvinorin A)-appropriate responding
presented graphically as mean±SEM; 90% drug appropriate was considered the minimum
value for generalization in an individual subject (consistent with training criteria). Rate of
responding is presented graphically as %control value (mean±SEM). Individual control values
for rate of responding were calculated as the mean of the three most recent consecutive vehicle-
training cycles prior to each test session.
Unconditioned behavioral effects (facial relaxation and ptosis)
Facial relaxation and ptosis
In separate studies, the effects of salvinorin A and selected compounds studied above were
determined in two unconditioned behavioral effects: (a) facial relaxation (partial or severe) and
(b) ptosis (partial or complete). These endpoints, as well as their potential translational
significance have been described recently (Butelman et al. 2008). Studies were carried out
using either a timecourse or cumulative dose-effect curve design (the latter with a 20 min inter-
injection interval, similarly to drug discrimination studies above). Discriminative effects of
salvinorin A (e.g., at 0.01 mg/kg, s.c.) occurred at doses that were devoid of robust overt
behavioral effects, by direct observation (Butelman et al. 2008). In these studies, we therefore
compared the effects the largest salvinorin A dose that can be administered s.c. (0.032 mg/kg;
due to solubility limitations) and compared it to its effects by the i.v. route (see below).
The cumulative duration of facial relaxation and ptosis behaviors within 1-min windows was
separately scored “blind” from videotapes of chaired subjects (i.e., scores could range 0–60 s
for facial relaxation or ptosis). Brief events less than 1 s in duration were not scored, in order
to avoid baseline behaviors, such as blinking. All time windows were selected a priori, using
standardized time and dose points.
Time windows were rated “blind” by a main trained rater, using the Observer XT System
(Noldus, Wageningen, Netherlands), as recently described in detail (Butelman et al. 2008).
The rater was previously trained and completed a periodic test of scoring reliability during
these studies. This resulted in a coefficient of variation of 6% when rating a 1-min time window
of peak robust pharmacological activity for salvinorin A, five independent times. Data
collection and statistical analyses were completed to the nearest 0.1 s.
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All observational studies were carried out with four subjects across conditions, using either a
timecourse design (0–60 min after injection) or in cumulative dosing sessions with 20 min
inter-injection interval, and scored time windows 14–15 min after each injection (i.e., timing
similar to drug discrimination cycles). The order of different experiments was unsystematic,
with consecutive experiments in the same subject separated by at least 72 h.
Timecourse studies
The effects of salvinorin A 0.032 mg/kg were compared by the i.v. vs. the s.c.route and
compared to i.v. vehicle (standard 1-min time windows were scored at 0–1, 1–2, 4–5, 14–15,
29–30, and 59–60 min after injection). This study determined whether salvinorin A, which is
reportedly sensitive to systemic degradation, is more effective by the i.v. vs. the s.c. route, due
to its greater predicted bioavailability (Hooker et al. 2008; Schmidt et al. 2005).
Cumulative dosing studies
Consistent with the more robust effects of i.v. vs. s.c. salvinorin A in the above study, all
cumulative dosing studies were carried out by the i.v. route. Subjects were studied with
intravenous salvinorin A (0.001–0.032 mg/kg), U69,593 (0.001–0.032 mg/kg), ICI204,448
(0.01–0.32 mg/kg), and psilocybin (0.01–0.1 mg/kg). Ketamine was not studied on these
dependent variables, due to its known effects on nystagmus, possibly confounding scoring of
ptosis (Condy et al. 2005).
Data analysis
Data for the two dependent variables (facial relaxation and ptosis) are presented separately as
mean±SEM, expressed as cumulative time of each behavior observed within a 1-min window.
When appropriate, data are analyzed by one- or two-way repeated measures analysis of
variance (ANOVA) followed by post hoc Newman–Keuls testing (SPSS Sigmastat). The α
level was set at p<0.05 throughout, values denoted as significant therefore used this p value as
a cutoff.
Drugs (all assays)
Salvinorin A (extracted in the Laboratory of Dr. T.E. Prisinzano) was dissolved in daily aliquots
in ethanol:Tween 80:sterile water vehicle (1:1:8 proportion, by volume). U69,593 (Pharmacia,
Kalamazoo, MI, USA), quadazocine mesylate (Sanofi-Winthrop, Malvern, PA, USA),
ICI204,448 (Tocris Bioscience, Ellisville, MO, USA), and SNC80 (Tocris Bioscience,
Ellisville, MO, USA) were dissolved in sterile water with the addition of two drops of lactic
acid (further dilutions were made with sterile water). Ketamine HCl (Fort Dodge, IA, USA)
was diluted with sterile water from stock solution (100 mg/ml). Ketanserin tartrate was
dissolved in 5% DMSO in sterile water (ketanserin dose is expressed as free base).
Bremazocine HCl (RBI), U50,488 (Pharmacia, Kalamazoo, MI, USA), fentanyl citrate (Sigma,
St. Louis, MO, USA), and psilocybin (kindly supplied by the National Institute on Drug Abuse
Research Technology Branch) were dissolved in sterile water. Drug doses are expressed as the
forms detailed above, unless stated. All drugs were injected s.c. in volumes of 0.05–0.16 ml/
kg in the drug discrimination studies. Drugs were injected either s.c. or i.v. in the facial
relaxation/ptosis studies, as indicated in text.
Results
Drug discrimination
Three subjects were trained to criterion (see “Methods”). Mean response rates in three
consecutive vehicle-training cycles were 2.7 responses/s (SEM 0.7). Repeated vehicle,
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administered as part of a three-cycle test, resulted in vehicle-appropriate responding (i.e., 0%
salvinorin A-appropriate responding) in all subjects and did not cause a robust change in
response rates (range of mean values in the three cycles of this test was 95–111% of control;
see Fig. 1). Cumulative salvinorin A was dose-dependently generalized by all subjects (Fig.
1) (generalization occurred at the 0.01-mg/kg dose in all subjects). Slight response rate-
decreasing effects of salvinorin A were detected at the fully generalized dose (Fig. 1).
Drug generalization tests—The centrally penetrating κ-agonists bremazocine, U69,593,
and U50,488 were generalized by all subjects, albeit with substantially different potency
(bremazocine>U69,593>salvinorin A>U50,488; Fig. 1). By contrast, the peripherally selective
κ-agonist ICI204,448 was only generalized by one of three subjects, up to doses that caused
response rate-decreasing effects. The μ-agonist fentanyl, the δ-agonist SNC80, the serotonergic
hallucinogen psilocybin, and the noncompetitive NMDA antagonist ketamine were not
generalized by any of the subjects, up to doses that caused rate-decreasing effects (Fig. 1). One
subject tested with ketamine emitted a maximum of 50% salvinorin A-appropriate responding,
at the highest doses (1 and 3.2 mg/kg).
Antagonism tests—The opioid antagonist quadazocine (0.32 mg/kg) fully prevented the
discriminative stimulus effects of salvinorin A in all subjects (Fig. 2). This quadazocine-
induced blockade was not surmounted by salvinorin A, up to the largest dose that could be
administered by the s.c. route (0.032 mg/kg; due to solubility limitations), in any subject. By
contrast, the 5HT2 antagonist ketanserin (0.1 mg/kg) did not cause blockade of the
discriminative effects of salvinorin A in any subject (Fig. 2). In control determinations (not
shown), each of these antagonists alone (quadazocine or ketanserin) was devoid of effect on
responding on three consecutive cycles, each preceded by vehicle administration. Effects of
salvinorin A and on unconditioned behavioral effects (facial relaxation and ptosis)
Timecourse studies—Pre-injection (baseline) scores for either endpoint (facial relaxation
or ptosis) were predominantly 0 s (from a 1-min time window), as were timecourse vehicle
determinations after i.v. vehicle (0–60 min; with standard time bins examined; Fig. 3).
Salvinorin A (0.032 mg/kg) by the s.c. route caused only slight effects on facial relaxation and
ptosis, with peak effects between 5 and 15 min after administration (Fig. 3). By contrast, this
salvinorin A dose administered by the i.v. route in the same subjects resulted in more robust
effects on both endpoints and a faster onset (robust effects were observed within 1–2 min of
i.v. administration). A two-way (time X condition ([vehicle, i.v. salvinorin A, and s.c.
salvinorin A]) repeated measures ANOVA for facial relaxation yielded a significant main effect
of condition (F[2,6]=5.95; p<0.04). Newman–Keuls post hoc tests showed that i.v. salvinorin
A produced greater facial relaxation than either s.c. salvinorin A or vehicle for the time
windows 0–1 and 4–5 min after administration. A similar two-way (time X condition (vehicle,
i.v. salvinorin, and s.c. salvinorin)) repeated measures ANOVA for ptosis yielded a significant
main effect of condition (F[2,6]=18.49; p<0.003) and a time X condition interaction (F[10,30]
=3.87; p<0.002). Newman–Keuls post hoc tests showed that i.v. salvinorin A produced greater
ptosis than vehicle for the time windows at 0–1, 1–2, 4–5, and 14–15 min after administration.
Newman–Keuls post hoc tests also show that s.c. salvinorin A administration produced greater
ptosis than vehicle for the time bins 4–5 and 14–15 min after administration.
Cumulative dose-effect curve studies—Pre-injection time windows for all subjects
resulted predominantly in scores of 0 s in either dependent variable, as above. In a vehicle
cumulative dosing procedure, with a 20-min inter-injection interval and time windows
quantified 14–15 min after each injection, scores of 0 s in either variable were predominantly
observed in all subjects (a line depicting mean values for the four vehicle cycles is presented
in Fig. 4).
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The effects of cumulative salvinorin A, U69,593, ICI204,88, and psilocybin were studied by
the i.v. route, since this route resulted in the more robust effects than the s.c. route (see above;
Fig. 4). Ketamine was not studied due to its known actions on nystagmus, possibly interfering
with ptosis scoring.
Salvinorin A (0.001–0.032 mg/kg) caused facial relaxation and ptosis, with clear dose-
dependent effects in the latter measure. A repeated measures ANOVA (F[4,12]=1.43; ns) did
not detect an effect of salvinorin A on facial relaxation in this cumulative dosing determination.
However, a similar ANOVA (F[4,12]=13.47; p<0.001) revealed a significant effect of
salvinorin A dose on ptosis. Newman–Keuls tests revealed that the effects of the largest
salvinorin A dose on ptosis (0.032 mg/kg) were significantly different from vehicle and all
other salvinorin A doses (0.001–0.01 mg/kg).
U69,593 (0.001–0.032 mg/kg) also caused increases in facial relaxation and ptosis, but again
with greater dose-dependent effects in the latter measure. A repeated measures ANOVA for
facial relaxation did not detect a significant effect of U69,593 (F[4,12]=1.84; ns). A repeated
measures ANOVA (F[4,12]=31.60; p<0.001) revealed a significant effect of U69,593 on
ptosis. Newman–Keuls tests revealed that the effects of the two largest U69,593 doses on ptosis
(0.01 and 0.032 mg/kg) were significantly different from vehicle and the two smaller U69,593
doses (0.001–0.0032 mg/kg).
ICI204,448 (0.01–0.032 mg/kg) produced robust facial relaxation only in one of four subjects,
whereas it caused dose-dependent ptosis in all subjects. A repeated measures ANOVA (F[4,12]
=1; ns) did not detect an effect of ICI204,448 on facial relaxation, under these conditions.
However, a repeated measures ANOVA (F[4,12]=6.61; p< 0.005) revealed a significant effect
of ICI204,448 on ptosis. Newman–Keuls tests revealed that the effects of the largest
ICI204,448 dose on ptosis (0.32 mg/kg) was significantly different from vehicle and the two
smallest ICI204,448 doses (0.01–0.032 mg/kg).
Psilocybin (0.01–0.1 mg/kg) did not result in facial relaxation in any of the subjects (0 s scores
were obtained throughout). Psilocybin likewise did not result in detectable ptosis, under these
conditions; the largest effect observed at the largest psilocybin dose (0.1 mg/kg) had a mean
value of 3.9 s (compared to a possible maximum of 60 s).
Quadazocine and naltrexone antagonism of salvinorin A-induced unconditioned behaviors
In two separate experiments, the salvinorin A cumulative dose-effect curve was re-determined
after quadazocine pretreatment (0.32 mg/kg, s.c.; 60 min pretreatment) or naltrexone
pretreatment (0.1 mg/kg, s.c.; 30 min pretreatment; Fig. 5). In both cases, a time window was
also examined 19–20 min after each antagonist alone. Values after each antagonist alone were
uniformly 0 s for all subjects, for facial relaxation and ptosis (not shown). Quadazocine did
not cause robust antagonism of salvinorin A-induced facial relaxation under these conditions,
whereas naltrexone depressed the salvinorin A dose-effect curve. However, a two-way
(salvinorin A dose X pretreatment condition ([no pretreatment, quadazocine or naltrexone
pretreatment]) repeated measures ANOVA did not reveal significant main effect of dose or
pretreatment condition, possibly due to the limited effects of salvinorin A alone (e.g., Fig. 3)
with these cumulative dosing parameters (not shown).
However, both quadazocine and naltrexone caused robust antagonism of the cumulative
salvinorin A dose-effect curve on ptosis. A two-way (salvinorin A dose X pretreatment
condition ([no pretreatment, quadazocine or naltrexone pretreatment]) repeated measures
ANOVA on ptosis revealed the main effects of salvinorin A dose (F[3,9]=12.63; p<0.00),
pretreatment (F[2,6]=7.19; p< 0.03), and their interaction (F[6,18]=5.79; p<0.002). Newman–
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Keuls tests revealed that both quadazocine and naltrexone pretreatment conditions were
different from salvinorin A alone.
Discussion
The widely available plant-derived hallucinogen, salvinorin A, is unique due to its high affinity
and efficacy at κ-receptors, whereas other abused drugs with hallucinogenic or dissociative/
psychotomimetic effects have 5HT2 (especially 5HT2A) agonist or NMDA antagonist effects
(Roth et al. 2002). We present herein the first drug discrimination assay using salvinorin A as
a training stimulus in nonhuman primates with high κ-receptor genetic homology to humans
(Butelman et al. 2007).
Consistent with recent data from rats (Baker et al. 2009), rhesus monkey trained to discriminate
salvinorin A generalized two centrally penetrating arylacetamide κ-agonists, U69,593 and
U50,488. In addition, we report here that the benzomorphan κ-agonist bremazocine was also
generalized in these primates, suggesting that structurally diverse κ-agonists share the
discriminative effects of salvinorin A. The potency order of these centrally acting κ-agonists
(bremazocine>U69,593>U50,488) is consistent with the potency order in other κ-receptor-
mediated endpoints in this species (France et al. 1994). Up to the largest dose that did not
decrease responding, the prototypical peripherally selective κ-agonist ICI204,448 was only
generalized in one of three subjects. ICI204,448 may only display relative peripheral
selectivity, based on behavioral/in vivo data (Butelman et al. 1999; Carey and Bergman
2001; Kumar et al. 2005), and this may likely underlie its partial effectiveness herein. Taken
together, these data indicate that central κ-agonist effects are predominantly involved in the
discriminative effects of salvinorin A in primates.
Other opioid receptor mechanisms, in addition to κ-receptors, were not apparently implicated
in this effect, since the μ-agonist fentanyl or the δ-agonist SNC80 were not generalized in any
subject, up to doses that decreased responding. Fentanyl and SNC80 are known to produce
operant effects in this species mediated respectively by μ-and δ-agonist mechanisms (Brandt
et al. 1999; Gerak and France 1996; Negus et al. 1993). Furthermore, the 5HT2-agonist
psilocybin and the NMDA antagonist ketamine, abused compounds with hallucinogenic or
dissociative/psychotomimetic effects, were likewise not generalized by any subject. Partial
generalization with ketamine (50% salvinorin A-appropriate responding) was observed in one
subject. It is known that NMDA antagonists can result in partial generalization in drug
discrimination assays, due to nonspecific behavioral changes, rather than qualitative
similarities with the relevant training drug (Koek et al. 1995). Therefore, this partial
generalization in one subject is not sufficient to suggest a clear similarity between the
discriminative stimulus effects of ketamine and salvinorin A.
Overall, the profile of drug discrimination findings supports the conclusion that the
interoceptive effects of salvinorin A are mediated by different receptors and are qualitatively
different from those of other known hallucinogenic/psychotomimetic compounds in humans.
This conclusion is also consistent with the recent report of a lack of generalization of salvinorin
A in rhesus monkeys trained to discriminate the 5HT2 hallucinogen DOM (1-(2,5-
dimethoxy-4-methylphenyl)-2-aminopropane (Li et al. 2008).
We also report the first data on the antagonism of the effects of salvinorin A in this drug
discrimination. The opioid antagonist quadazocine, at a dose (0.32 mg/kg) known to be
sufficient to block κ-receptor-mediated effects in this species (Negus et al. 1993), prevented
the discriminative effects of salvinorin A herein. This robust antagonism could not be
surmounted, up to the largest dose of salvinorin A that could be administered subcutaneously,
due to solubility limitations. Other opioid antagonists (e.g., naltrexone, see below) were not
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used in the drug discrimination assay to minimize the potential interference with appetitive
tasks in nonhuman primates (France and Morse 1989; Williams et al. 1999). By contrast to the
opioid antagonist quadazocine, the 5HT2-antagonist ketanserin did not block the
discriminative effects of salvinorin A, under similar conditions. The dose of ketanserin
employed herein (0.1 mg/kg) is sufficient to block behavioral effects of 5HT2-agonists in this
species (Li et al. 2009). Taken together, these antagonist studies are also consistent with the
conclusion that opioid (κ) and not serotonergic 5HT2 receptor mechanisms underlie the
behavioral effects of salvinorin A, contrasting with classic hallucinogens.
It has been previously reported that κ-agonists have sedative effects in humans, in addition to
their psychotomimetic/dysphoric effects (Pfeiffer et al. 1986; Ur et al. 1997). Sedative and
postural effects (e.g., postural relaxation) of centrally penetrating κ-agonists have also been
reported in rhesus monkeys (Butelman et al. 1999; Dykstra et al. 1987). We have recently
demonstrated that particular unconditioned effects related to the above (facial relaxation and
ptosis) can be quantified in primates (Butelman et al. 2008) and may be potentially helpful as
translational measures that can be applied for the study of salvinorin A (and more generally
κ-opioid) effects in humans (Chernik et al. 1990; Miner et al. 2002). Furthermore, actual
hallucinogenic effects in nonhuman primates are not easily quantified (Castner and Goldman-
Rakic 1999; Davis et al. 1978). For example, visual and hand “tracking” (presumed behavioral
correlates of hallucinations in non-verbal species; Castner and Goldman-Rakic 2003) were
occasionally observed with salvinorin A in these studies. However, these endpoints were not
easily amenable to quantification herein (e.g., in terms of intensity or duration). Therefore,
facial relaxation and ptosis may be endpoints particularly suitable for the quantitative
translational analysis of behavioral effects of salvinorin A, including its potential ultra-rapid
onset (Butelman et al. 2008; Hooker et al. 2008).
We have recently reported that i.v. bolus salvinorin A caused robust facial relaxation in rhesus
monkeys, and that these effects could be prevented and reversed by the clinically available
opioid antagonist nalmefene but were not blocked by ketanserin (Butelman et al. 2008). We
found here that the largest salvinorin A dose (0.032 mg/kg) that could be administered
practically only produced relatively small effects on these unconditioned endpoints by the s.c.
route and displayed a slower onset than by the i.v. route (e.g., 5–15 vs. 1–2 min). This is the
first comparison of the behavioral effects of salvinorin A by these routes, widely used in
behavioral pharmacology studies. Overall, findings are consistent with the value of the i.v.
route as a useful substitute to quantify the effects of drugs commonly abused by the smoking
route, such as those containing salvinorin A, likely due to fast onset and greater bioavailability
by the i.v. route (Hooker et al. 2009; Rose et al. 1999; Schmidt et al. 2005; Tanda et al.
2000).
Consistent with the greater effects observed by the i.v. route in the bolus comparison (above),
cumulative dose-effect curve studies were designed with salvinorin A and a subset of the
compounds studied in the drug discrimination assay (using timing conditions similar to those
in the drug discrimination assay). Salvinorin A (as well as U69,593) caused facial relaxation
in some subjects in this cumulative dosing determination. This effect did not reach significance,
possibly due to the relatively short duration of salvinorin A-induced facial relaxation, partially
dissipating by 15 min (i.e., the time window used in the cumulative dosing determination). For
comparison, a robust effect of salvinorin A on facial relaxation was observed in bolus i.v.
administration in these subjects (e.g., up to 5 min after administration; see above).
Salvinorin A, as well as U69,593 caused robust dose-dependent ptosis in all subjects, in these
cumulative determinations, similar to the bolus determination herein and a recent study
(Butelman et al. 2008). ICI204,448 was also ineffective in causing facial relaxation herein, but
caused ptosis, albeit with considerably less potency than salvinorin A or U69,593. The
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maximum dose of ICI204,448 used herein is larger than that needed to cause a neuroendocrine
effect mediated by κ-receptors outside the blood-brain barrier in this species (prolactin release;
Butelman et al. 1999). These data, together with the generalization to ICI204,448 in only one
of three subjects in the drug discrimination above, suggest that relatively large doses of
ICI204,448 can produce centrally mediated effects. Consistent with this possibility, large doses
of ICI204,448 were also able to produce limited sedation in nonhuman primates (Butelman et
al. 1999). Other, more recently developed κ-receptor agonists do exhibit greater peripheral
selectivity than ICI204,448 itself (Kumar et al. 2005; Shaw et al. 1989).
We also report here that the opioid antagonist quadazocine (which robustly prevented the
discriminative effects of salvinorin A above and previously; Butelman et al. 2004) also fully
prevented the effects of salvinorin A in ptosis. A similar profile was observed with the clinically
available antagonist naltrexone, at a dose (0.1 mg/kg) known to block the behavioral effects
of arylacetamide κ-agonists in this species (Ko et al. 1998).
The serotonergic hallucinogen psilocybin did not cause either facial relaxation or ptosis, up to
the largest dose administered. The psilocybin doses studied are in the upper range of those
studied for operant self-administration studies in this species (Fantegrossi et al. 2004). We have
also recently reported that ketanserin did not block the effects of salvinorin A in either facial
relaxation or ptosis (Butelman et al. 2008). These findings, taken together with the inactivity
of psilocybin and ketanserin in the drug discrimination assay (above), underscore the
mechanistic divergence of salvinorin A to that of classic serotonergic hallucinogens.
Overall, these data show for the first time in nonhuman primates that the discriminative cue
produced by salvinorin A is predominantly mediated by agonist effects at central κ-receptors
and is not shared by agonists acting at other opioid receptors (μ or δ). Furthermore, abused
compounds with known classic hallucinogenic (psilocybin) or psychotomimetic/dissociative
effects in humans (ketamine) do not share the discriminative cue produced by salvinorin A.
Together with prior drug discrimination data (Baker et al. 2009; Butelman et al. 2004; Li et al.
2008; Willmore-Fordham et al. 2007), these findings underscore the functional uniqueness of
salvinorin A as a widely available powerful hallucinogen. We further show here that these
general conclusions can also be supported from studies with unconditioned endpoints (facial
relaxation and ptosis). These endpoints (unlike drug discrimination) do not require extensive
subject training and may be of translational value in the study of salvinorin A or, more
generally, the κ-opioid system in humans.
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Discriminative effects of salvinorin A and other ligands in subjects trained to discriminate
salvinorin A (0.015 mg/kg; n=3) from vehicle. Upper panel: percent salvinorin A-appropriate
responding; lower panel: rate of responding. Abscissae: cumulative dose after s.c.
administration (milligrams per kilogram). Ordinate (upper panel): percent salvinorin A-
appropriate responding; ordinate (lower panel): rate of responding expressed as percentage of
control rates (control rate was the mean rate of responding for the three prior vehicle-training
cycles for each subject). Data are mean±SEM, selected SEM omitted for clarity
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Antagonism of the discriminative effects of salvinorin A, after pretreatment with either
quadazocine (0.32 mg/kg) or ketanserin (0.1 mg/kg). Other details as in Fig. 1
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Timecourse of salvinorin A (0.032 mg/kg, n=4) by the intravenous or subcutaneous route, on
facial relaxation (upper panel) and ptosis (lower panel). Abscissae: time from the end of
injection (minutes). Ordinates: behavioral score for each behavior, within a 1-min bin (scores
could therefore range from 0 to 60 s). Data are mean±SEM
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Effects of salvinorin A and other ligands on facial relaxation (upper panel) and ptosis (lower
panel). Abscissae: cumulative dose after i.v. administration (milligrams per kilogram).
Ordinates: behavioral score for each behavior, within a 1-min bin, measured 14–15 min after
each injection. Data are mean±SEM
Butelman et al. Page 17














Antagonism of the effects of salvinorin A on ptosis, after pretreatment with either quadazocine
(0.32 mg/kg) or naltrexone (0.1 mg/kg). Abscissa: cumulative salvinorin A dose after i.v.
administration (milligrams per kilogram). Ordinate: ptosis score. Other details as in Fig. 4
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